Literature DB >> 3959083

Identification of a distinct class of vinblastine binding sites on microtubules.

M A Jordan, R L Margolis, R H Himes, L Wilson.   

Abstract

Vinblastine, at concentrations above approximately 1 to 2 microM, causes depolymerization of steady-state bovine brain microtubules in vitro by a fraying of microtubule ends into protofilament-like spirals. Microtubule depolymerization is associated with the binding of vinblastine in approximately molar stoichiometry to tubulin in microtubules with apparent low affinity, as determined by binding experiments with radiolabeled vinblastine and by the ability of vinblastine to inhibit DEAE-dextran decoration of microtubule surfaces. Our data suggest that depolymerization occurs by a propagated mechanism, initially involving binding of vinblastine to a limited number of available sites on microtubule surfaces. This appears to cause loosening of protofilament associations which results in the exposure of new vinblastine-binding sites. Additional vinblastine binding in turn results in further loosening of protofilament associations. Such loosening, when it occurs at microtubule ends, results in protofilament-like splaying and end-wise depolymerization. Microtubule depolymerization appears mechanistically distinct from inhibition of microtubule polymerization by the drug, which is associated with the binding of vinblastine to small numbers of high-affinity binding sites on tubulin at one or both microtubule ends.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3959083     DOI: 10.1016/0022-2836(86)90406-7

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro.

Authors:  R J Vasquez; B Howell; A M Yvon; P Wadsworth; L Cassimeris
Journal:  Mol Biol Cell       Date:  1997-06       Impact factor: 4.138

2.  CLASP2 Has Two Distinct TOG Domains That Contribute Differently to Microtubule Dynamics.

Authors:  Takahisa Maki; Ashley D Grimaldi; Sotaro Fuchigami; Irina Kaverina; Ikuko Hayashi
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

3.  Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.

Authors:  M P Rivera-Fillat; J Pallarés-Trujillo; C Domènech; M R Grau-Oliete
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

4.  Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain.

Authors:  Israr A Khan; Richard F Ludueña
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

5.  Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.

Authors:  Olga Azarenko; Tatiana Okouneva; Keith W Singletary; Mary Ann Jordan; Leslie Wilson
Journal:  Carcinogenesis       Date:  2008-10-23       Impact factor: 4.944

6.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

Authors:  M A Jordan; R J Toso; D Thrower; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Differential in vitro action of S-12363, a new vinblastine derivative, and of its epimer on microtubule proteins.

Authors:  M Wright; M Garès; P Verdier-Pinard; A Moisand; M Berlion; J J Legrand; J P Bizzari
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Vinblastine suppresses dynamics of individual microtubules in living interphase cells.

Authors:  R Dhamodharan; M A Jordan; D Thrower; L Wilson; P Wadsworth
Journal:  Mol Biol Cell       Date:  1995-09       Impact factor: 4.138

9.  (-)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin.

Authors:  Ruoli Bai; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2016-06-13       Impact factor: 4.013

10.  A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).

Authors:  Eric S Schafer; Rachel E Rau; Stacey Berg; Xiaowei Liu; Charles G Minard; David D'Adamo; Rachael Scott; Larisa Reyderman; Gresel Martinez; Sandhya Devarajan; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2018-05-02       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.